DE69532835D1 - Verwendung von isolierten Domänen des Typ-IV-Kollagens zur Modifikation von Zell- und Gewebeinteraktionen - Google Patents

Verwendung von isolierten Domänen des Typ-IV-Kollagens zur Modifikation von Zell- und Gewebeinteraktionen

Info

Publication number
DE69532835D1
DE69532835D1 DE69532835T DE69532835T DE69532835D1 DE 69532835 D1 DE69532835 D1 DE 69532835D1 DE 69532835 T DE69532835 T DE 69532835T DE 69532835 T DE69532835 T DE 69532835T DE 69532835 D1 DE69532835 D1 DE 69532835D1
Authority
DE
Germany
Prior art keywords
cell
collagen
type
mesoglea
blockage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69532835T
Other languages
English (en)
Other versions
DE69532835T2 (de
Inventor
Michael P Sarras Jr
Billy G Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas Medical Center
Original Assignee
University of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas Medical Center filed Critical University of Kansas Medical Center
Publication of DE69532835D1 publication Critical patent/DE69532835D1/de
Application granted granted Critical
Publication of DE69532835T2 publication Critical patent/DE69532835T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE69532835T 1994-06-30 1995-06-30 Verwendung von isolierten Domänen des Typ-IV-Kollagens zur Modifikation von Zell- und Gewebeinteraktionen Expired - Fee Related DE69532835T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/268,969 US5567609A (en) 1994-06-30 1994-06-30 Use of isolated domains of type IV collagen to modify cell and tissue interactions
US268969 1994-06-30

Publications (2)

Publication Number Publication Date
DE69532835D1 true DE69532835D1 (de) 2004-05-06
DE69532835T2 DE69532835T2 (de) 2005-02-10

Family

ID=23025295

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69524094T Expired - Fee Related DE69524094T2 (de) 1994-06-30 1995-06-30 Verwendung von isolierten domänen des typ-iv-kollagens zur modifikation von zell- und gewebeinteraktionen
DE69532835T Expired - Fee Related DE69532835T2 (de) 1994-06-30 1995-06-30 Verwendung von isolierten Domänen des Typ-IV-Kollagens zur Modifikation von Zell- und Gewebeinteraktionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69524094T Expired - Fee Related DE69524094T2 (de) 1994-06-30 1995-06-30 Verwendung von isolierten domänen des typ-iv-kollagens zur modifikation von zell- und gewebeinteraktionen

Country Status (9)

Country Link
US (7) US5567609A (de)
EP (2) EP0767676B1 (de)
AT (2) ATE262922T1 (de)
AU (1) AU3000895A (de)
DE (2) DE69524094T2 (de)
DK (2) DK1129721T3 (de)
ES (2) ES2164160T3 (de)
PT (2) PT767676E (de)
WO (1) WO1996000582A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567609A (en) 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) * 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
EP0878480A1 (de) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller Verfahren zur Förderung der Nerven-Regenerierung
AU748751B2 (en) * 1998-03-27 2002-06-13 University Of Kansas Medical Center The use of isolated domains of type IV collagen to modify cell and tissue interactions
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
IL140239A0 (en) * 1998-06-17 2002-02-10 Beth Israel Hospital Anti-angiogenic proteins and methods of use thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US20010018579A1 (en) 1998-12-18 2001-08-30 Walter Klemp Disposable absorbent garment having stretchable side waist regions
WO2000059532A1 (en) * 1999-04-01 2000-10-12 Biostratum, Inc. The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
US6893812B2 (en) * 2000-05-30 2005-05-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Three-dimensional ex vivo angiogenesis system
CN100447155C (zh) * 2001-05-23 2008-12-31 中国科学院上海上海生命科学研究院 具有抑制内皮细胞生长活性的重组人内皮生长抑制蛋白
EP1573025A4 (de) 2001-07-27 2006-07-19 Univ Kansas Medical Center Kristallstruktur des typ-iv-collagen-nc1-domäne-hexamers
WO2004067762A2 (en) * 2003-01-27 2004-08-12 University Of Kansas Medical Center Crystallized structure of type iv collagen nc1 domain hexamer
WO2004100769A2 (en) * 2003-05-09 2004-11-25 Falco Frank J Methods for using gadolinium as a contrast media
US7432413B2 (en) 2005-12-16 2008-10-07 The Procter And Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US8057450B2 (en) 2006-03-31 2011-11-15 The Procter & Gamble Company Absorbent article with sensation member
US8491558B2 (en) 2006-03-31 2013-07-23 The Procter & Gamble Company Absorbent article with impregnated sensation material for toilet training
US8664467B2 (en) 2006-03-31 2014-03-04 The Procter & Gamble Company Absorbent articles with feedback signal upon urination
EP2088979A2 (de) 2006-12-04 2009-08-19 The Procter & Gamble Company Saugfähige artikel mit grafischen elementen
US9012160B2 (en) * 2008-06-16 2015-04-21 Abraham Amir Monitoring skin metabolism products for evaluating burn injury
WO2013170433A1 (en) 2012-05-15 2013-11-21 The Procter & Gamble Company Absorbent article having characteristic waist end

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021404A (en) 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
US6440729B1 (en) * 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen

Also Published As

Publication number Publication date
AU3000895A (en) 1996-01-25
ATE209043T1 (de) 2001-12-15
ATE262922T1 (de) 2004-04-15
US5691182A (en) 1997-11-25
PT1129721E (pt) 2004-07-30
US6419924B1 (en) 2002-07-16
US6448222B1 (en) 2002-09-10
PT767676E (pt) 2002-03-28
ES2217050T3 (es) 2004-11-01
EP1129721A3 (de) 2001-11-14
DE69524094T2 (de) 2002-04-18
US6384012B1 (en) 2002-05-07
DK1129721T3 (da) 2004-06-28
EP1129721A2 (de) 2001-09-05
EP1129721B1 (de) 2004-03-31
US5567609A (en) 1996-10-22
ES2164160T3 (es) 2002-02-16
DK0767676T3 (da) 2002-05-21
WO1996000582A1 (en) 1996-01-11
US20030013194A1 (en) 2003-01-16
EP0767676B1 (de) 2001-11-21
DE69532835T2 (de) 2005-02-10
DE69524094D1 (de) 2002-01-03
US5856184A (en) 1999-01-05
US6680293B2 (en) 2004-01-20
EP0767676A1 (de) 1997-04-16

Similar Documents

Publication Publication Date Title
DE69532835D1 (de) Verwendung von isolierten Domänen des Typ-IV-Kollagens zur Modifikation von Zell- und Gewebeinteraktionen
NZ319646A (en) Use of a rar-y-specific agonist ligand for increasing the rate of apoptosis
DE1100751T1 (de) Herstellung von anionischen nanokompositen und ihre verwendung als retentions- und entwässerungshilfsmittel bei der papierherstellung
DE69221060T2 (de) Verwendung von Emzymen und Flockungsmitteln zur Erhöhung der Entwässerungsneigung von Papierpulpe
DE69017921T2 (de) Lactoferrinhydrolysat zur Verwendung als tyrosinagehemmendes Mittel.
DE69404373D1 (de) Verwendung von 4-,4- und 5-, oder 4- und 6-substituierten Resorcin-Derivaten in kosmetischen oder dermopharmazeutischen Depigmentierungsmitteln
DE69000837T2 (de) Relativbeantwortungssystem fuer ein aufzugsverteilungssystem mit "kuenstlicher intelligenz" zum aendern von bonus- und strafbestimmungen.
DE69221443T2 (de) Flüssigkristallichtventil und Informationsprozessor unter Verwendung desselben
DE59309589D1 (de) Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen
DE69624918D1 (de) Verwendung von pseudopterosin zur förderung der wundheilung
DE69919684D1 (de) Verwendung von isolierten domänen des type-iv-kollagens zur änderung der zell- und gewebewechselwirkung
Seeds et al. Plasminogen activators and their interaction with the extracellular matrix in neural development, plasticity and regeneration
ATE233801T1 (de) Flüssigkristallkompositmaterial und vorrichtung, die dieses enthält
DK0914169T3 (da) Materialer til anvendelse i glaukomfiltreringsanordninger
DE69425870D1 (de) Entwicklungseinheit mit Vorrichtung zur Regelung der Entwicklermenge
HUP9901757A2 (hu) Az integrin szabályozás/jelzés citoplazmás modulátorai
Holgate Water Quality: DETR consultation on new regulations for drinking water
DE69634363D1 (de) Vorläufer von normalen neuralen epithelzellen
ATE203858T1 (de) Verfahren zum erfassen des energieeinsparpotentials eines elektrischen energieverbrauchersystems und verfahren zum betreiben eines elektrischen engergieverbrauchersystems
DE69216253T2 (de) 2-(2-benzo b thienyl)-3-methoxyacrylat- und -2-iminoacetat-derivate zur verwendung als pestizide
BR9802788A (pt) Formador de tela dupla
Wortmann Medical studies of the circadian rhythm and the behaviour of station personnel in an Antarctic research station
Boyet et al. A Statistical Analysis of Factors Affecting Water Prices in Small Municipalities
JPS6462072A (en) Picture reader
Loper et al. Water Withdrawals and Consumption in Pennsylvania, 1984

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee